Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 38 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Koutras, Angelos [Clear All Filters]
alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies..
BMC Clin Pathol. 14, 28.
(2014). The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping..
Breast. 23(3), 234-43.
(2014). Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group..
J Transl Med. 15(1), 30.
(2017). Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer..
Clin Breast Cancer. 14(5), 330-8.
(2014). Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study..
PLoS One. 11(10), e0164013.
(2016). Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials..
Clin Breast Cancer. 18(1), 53-62.e3.
(2018). Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab..
ESMO Open. 4(2), e000441.
(2019). Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes..
PLoS One. 9(3), e91407.
(2014). Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel..
PLoS One. 7(6), e37946.
(2012).
(2014). Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes..
Breast Cancer Res Treat. 158(2), 307-21.
(2016). Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab..
Cancer Genomics Proteomics. 15(6), 461-471.
(2018).
(2013). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015). Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study..
PLoS One. 13(12), e0207707.
(2018). Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study..
Oncol Rep. 27(1), 216-24.
(2012). Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel..
Anticancer Res. 32(10), 4569-80.
(2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy..
J Transl Med. 10, 10.
(2012). Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study..
Histol Histopathol. 30(9), 1129-41.
(2015). Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial..
PLoS One. 8(7), e69256.
(2013). Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia..
Mol Clin Oncol. 4(2), 211-220.
(2016). MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer..
J Transl Med. 14(1), 136.
(2016). Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer..
Cancer Genomics Proteomics. 16(3), 195-206.
(2019). p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015).
(2011).